English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The comparative toxicity test was performed on male rats, which were topically treated with a volume of 0.25 g/kg of 0.12% dexamethasone valerate (DV-17) ointment as a test drug, and 0.1% dexamethasone (DEX), 0.05% fluocinonide (FAA), 0.025% beclomethasone dipropionate (BMD), 0.1% hydrocortisone butyrate (HB), 0.05% clobetasol propionate (CP) and 0.12% betamethasone valerate (BMV) ointments as an active control drug for 30 consecutive days to evaluate on the effects of following items: body weight changes, adrenal functions (organ weight, histological changes of the cortex and serum contents of corticosterone), pathological changes of hypophysis and lymphatic systems (thymus, mesenteric lymph nodes and spleen), and skin changes. Furthermore, the recovery test was also carried out. The severity of topical toxicities was in parallel with that of systemic toxicities. Judging from the results obtained in this study, the potency of toxicities among seven corticosteroid ointments appeared to be as follows: FAA greater than DEX much greater than CP greater than BMV, DV-17 greater than HB greater than BMD. The toxicities of DV-17 were comparable with that of BMV, and these side effects were found to be minimized on the recovery test.

COMPARATIVE TOXICITY TEST OF DEXAMETHASONE VALERATE (DV-17) AND OTHER STEROID OINTMENTS IN RATS